Deep Drug Discovery Unsupervised fragment-to-drug generation

Jordi Mestres jordi.mestres@chemotargets.com






ALL SLIDES ARE STRICTLY CONFIDENTIAL FOR INTERNAL DISTRIBUTION ONLY

Main components required to approach the dream

SurfScan

A method to perform fragment screening on complete protein surfaces



FragSteer


A method to differentiate stable from compatible interacting fragments


ChemBang


A method to expand the chemical space around stable fragments



A model suite to anticipate binding and safety of small molecules







SurfScan works




Figure 2. Selection of the preclinical candidate (GLYN122) from analogue expansion of a hit compound (GLYN026) derived from two adjacent chemical fragments obtained from virtual protein surface scanning.

Chemotargets' Deep Drug Discovery (D³) platform

